You've learned that you have diffuse large B-cell lymphoma (DLBCL ... and fast-growing type of lymphoma. But with the right treatment, about 2 out of 3 people with this cancer can be cured.

This type of lymphoma mainly affects older people over the age of 50 years, but it can also affect children and younger adults. Treatment for diffuse large B-cell lymphoma The current recommended ...

Cochrane: "CAR T-cell therapy for people with diffuse large B-cell lymphoma which returns after treatment or no longer responds to treatment." HemaSphere: "CAR-T Cell Therapy in Diffuse Large B ...

Researchers recently concluded that the care received by patients treated by the Veterans Health Administration for diffuse large B-cell lymphoma met the standard of care across races and ...

Anderson's longtime publicist Glenn Schwartz confirmed the news of his death to PEOPLE ... with diffuse large B-cell lymphoma, the most common type of non-Hodgkin lymphoma. "He is survived by ...

Liso-Cel is a type of CAR T-cell therapy — a revolutionary approach that uses a patient's own immune cells to fight cancer.

Long-term data gathered from the TRANSCEND NHL trial have shown that this treatment approach can significantly improve survival.

which estimates that it will become an option for around 600 people per year in England. The guidance covers patients with diffuse large B-cell lymphoma, high-grade B-cell lymphoma, primary ...

diffuse large B-cell lymphoma (DLBCL) not otherwise specified who are ineligible for autologous stem cell transplant (ASCT). With this approval, this Columvi combination is the first bispecific ...

These chronic diseases contrast with the aggressive non-Hodgkin lymphoma subtype, diffuse large B-cell lymphoma ... while patients with indolent diseases survive for a comparatively long time ...

This study presents a valuable finding on the direct cytotoxic effects of DuoHexaBody-CD37 in diffuse large B-cell lymphoma, mediated via SHP-1 activation and antibody clustering, independent of ...

“People with R/R DLBCL not eligible for ASCT represent a challenging population, especially those with primary refractory disease or early relapse whose need for a readily accessible and ...